Press Release Apr 15 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Isoproterenol Hydrochloride Injection. The injection is indicated for improving hemodynamic status in patients experiencing certain types of shock and for treating bronchospasm during anesthesia. The product will be manufactured at Zydus's facility in Jarod, India. This approval adds to Zydus's portfolio, which now includes a significant number of approvals since the filing process began.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Apr 11 2023
- Press Release Apr 10 2023
- Press Release Apr 06 2023
- Press Release Mar 28 2023
- Press Release Mar 25 2023
Later from Zydus Lifesciences
- Press Release Apr 18 2023
- Press Release Apr 19 2023
- Press Release Apr 20 2023
- Zydus Lifesciences Limited Press Release Apr 24 2023
- Press Release Apr 25 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences